Drug-eluting balloon: Very short-term exposure and overlapping
- 1 January 2009
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 101 (01), 201-206
- https://doi.org/10.1160/th08-06-0387
Abstract
Paclitaxel balloon coating has shown promising effects in inhibiting restenosis in initial clinical trials. The aim of the present study was to evaluate the influence of two critical features of drug-eluting balloon (DEB) application – inflation time and increased dose due to overlapping balloons. Fifty-six stainless steel stents were implanted in the left anterior descending and circumflex coronary arteries of 28 domestic pigs using a 1.2:1.0 overstretch ratio. Stents were mounted on conventional un-coated and paclitaxel-coated angioplasty balloon catheters. The animals were randomized to five different treatments with a range of short (10 seconds [s] inflation using 1 DEB) to extended (2x60 s inflation using 2 DEB) intima contact time. After 28 days, quantitative angiography and histomorphometry of the stented arteries was performed on a total of 23 pigs. Paclitaxel balloon coating led to a marked reduction of parameters characterizing in-stent stenosis: Late lumen loss was 1.37 ± 0.49 mm for uncoated balloons, 0.23 ± 0.42 mm for one coated balloon 60 s inflation time, 0.37 ± 0.28 mm for 10 s inflation time and 0.30 ± 0.19 mm for the vessel segment treated by two coated balloons with 60 s inflation each. Neointimal areas were 4.26 ± 1.18, 1.68 ± 0.23, 1.83 ± 0.40 and 1.67 ± 0.46 mm², respectively (p=0.001 versus control, p>0.05 between paclitaxel-treated groups). Despite the marked reduction of neointimal proliferation, endothelialization of stent struts was present in all samples. DEB were found to effectively reduce neointimal proliferation regardless of inflation time and dose within the tested range. No adverse reactions were seen as dose was increased to more than three times the clinically tested dose.Keywords
This publication has 17 references indexed in Scilit:
- Unanswered Questions — Drug-Eluting Stents and the Risk of Late ThrombosisNew England Journal of Medicine, 2007
- Local paclitaxel delivery after coronary stenting in an experimental animal modelThrombosis and Haemostasis, 2007
- Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon CatheterNew England Journal of Medicine, 2006
- Retention of paclitaxel in cancer cells for 1 week in vivo and in vitroCancer Chemotherapy and Pharmacology, 2006
- Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary modelCardiovascular Research, 2004
- Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of RestenosisCirculation, 2004
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo Using Local Drug DeliveryCirculation, 1997
- Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine modelJournal of the American College of Cardiology, 1992